A detailed history of Farallon Capital Management LLC transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Farallon Capital Management LLC holds 8,208,123 shares of BEAM stock, worth $220 Million. This represents 1.01% of its overall portfolio holdings.

Number of Shares
8,208,123
Previous 7,913,123 3.73%
Holding current value
$220 Million
Previous $185 Million 8.47%
% of portfolio
1.01%
Previous 0.9%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$22.57 - $33.14 $6.66 Million - $9.78 Million
295,000 Added 3.73%
8,208,123 $201 Million
Q2 2024

Aug 14, 2024

BUY
$21.22 - $32.66 $72.2 Million - $111 Million
3,401,370 Added 75.39%
7,913,123 $185 Million
Q1 2024

May 15, 2024

BUY
$23.46 - $45.07 $9.52 Million - $18.3 Million
406,000 Added 9.89%
4,511,753 $149 Million
Q4 2023

Feb 14, 2024

BUY
$17.69 - $30.76 $72.6 Million - $126 Million
4,105,753 New
4,105,753 $112 Million
Q3 2023

Nov 14, 2023

BUY
$23.01 - $32.46 $103 Million - $145 Million
4,481,839 New
4,481,839 $108 Million
Q2 2023

Aug 14, 2023

BUY
$29.32 - $35.99 $281,501 - $345,539
9,601 Added 0.28%
3,441,522 $110 Million
Q1 2023

May 15, 2023

BUY
$30.15 - $48.79 $964,800 - $1.56 Million
32,000 Added 0.94%
3,431,921 $105 Million
Q4 2022

Feb 14, 2023

SELL
$36.73 - $51.6 $8.5 Million - $11.9 Million
-231,350 Reduced 6.37%
3,399,921 $133 Million
Q3 2022

Nov 14, 2022

BUY
$39.79 - $70.31 $6.33 Million - $11.2 Million
159,000 Added 4.58%
3,631,271 $173 Million
Q2 2022

Aug 15, 2022

BUY
$29.86 - $62.36 $26.2 Million - $54.7 Million
877,884 Added 33.84%
3,472,271 $134 Million
Q1 2022

May 16, 2022

BUY
$53.73 - $82.16 $17.7 Million - $27.1 Million
329,342 Added 14.54%
2,594,387 $149 Million
Q4 2021

Feb 14, 2022

BUY
$68.02 - $99.06 $37.2 Million - $54.2 Million
547,455 Added 31.87%
2,265,045 $181 Million
Q3 2021

Nov 15, 2021

BUY
$84.37 - $133.6 $18.4 Million - $29.1 Million
217,590 Added 14.51%
1,717,590 $149 Million
Q2 2021

Aug 13, 2021

BUY
$64.12 - $128.71 $58.2 Million - $117 Million
907,519 Added 153.17%
1,500,000 $193 Million
Q1 2021

May 17, 2021

BUY
$71.28 - $120.75 $30.1 Million - $51 Million
422,317 Added 248.18%
592,481 $47.4 Million
Q1 2020

May 15, 2020

BUY
$13.31 - $29.2 $2.26 Million - $4.97 Million
170,164 New
170,164 $3.06 Million

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.89B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track Farallon Capital Management LLC Portfolio

Follow Farallon Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Farallon Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Farallon Capital Management LLC with notifications on news.